Editorial on "Cancer and the microbiota" published in Science

Annals of Translational Medicine

Volumn 3, Issue 13, 2015, Pages

  Hamm, Alison K ^a   Weir, Tiffany L ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015461944     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.07.16     Document Type: Editorial

References (58)

1. Garrett WS. Cancer and the microbiota. Science 2015;348:80-6.
2. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014;15:317-28.
3. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer 2013;13:800-12.
4. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014;12:661-72.
5. Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep 2014;16:406.
6. Ohtani N. Microbiome and cancer. Semin Immunopathol 2015;37:65-72.
7. Abreu MT, Peek RM Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology 2014;146:1534-1546.e3.
8. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
9. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011;6:e16393.
10. Weir TL, Manter DK, Sheflin AM, et al. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 2013;8:e70803.
11. Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014;9:e83744.
12. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.
13. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.
14. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
15. Baxter NT, Zackular JP, Chen GY, et al. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome 2014;2:20.
16. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506:371-5.
17. Tjalsma H, Boleij A, Marchesi JR, et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012;10:575-82.
18. Riley DR, Sieber KB, Robinson KM, et al. Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. PLoS Comput Biol 2013;9:e1003107.
19. Vizcaino MI, Crawford JM. The colibactin warhead crosslinks DNA. Nat Chem 2015;7:411-7.
20. Jinadasa RN, Bloom SE, Weiss RS, et al. Cytolethal distending toxin: a conserved bacterial genotoxin that blocks cell cycle progression, leading to apoptosis of a broad range of mammalian cell lineages. Microbiology 2011;157:1851-75.
21. Lu R, Wu S, Zhang YG, et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis 2014;3:e105.
22. Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206.
23. Kelly D, Mulder IE. Microbiome and immunological interactions. Nutr Rev 2012;70:S18-30.
24. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400.
25. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014;14:736-46.
26. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012;51:64-74.
27. Hu BY, Weick JP, Yu J, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A 2010;107:4335-40.
28. Zackular JP, Baxter NT, Iverson KD, et al. The gut microbiome modulates colon tumorigenesis. MBio 2013;4:e00692-13.
29. Rappaport SM. Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol 2011;21:5-9.
30. Roberts AB, Wallace BD, Venkatesh MK, et al. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 2013;84:208-17.
31. Gill CI, Rowland IR. Diet and cancer: assessing the risk. Br J Nutr 2002;88:S73-87.
32. Loh YH, Jakszyn P, Luben RN, et al. N-Nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. Am J Clin Nutr 2011;93:1053-61.
33. Russell WR, Hoyles L, Flint HJ, et al. Colonic bacterial metabolites and human health. Curr Opin Microbiol 2013;16:246-54.
34. Pegg AE. Toxicity of polyamines and their metabolic products. Chem Res Toxicol 2013;26:1782-800.
35. Hanfrey CC, Pearson BM, Hazeldine S, et al. Alternative spermidine biosynthetic route is critical for growth of Campylobacter jejuni and is the dominant polyamine pathway in human gut microbiota. J Biol Chem 2011;286:43301-12.
36. Bernstein H, Bernstein C, Payne CM, et al. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009;15:3329-40.
37. Irrazábal T, Belcheva A, Girardin SE, et al. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 2014;54:309-20.
38. Islam KB, Fukiya S, Hagio M, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011;141:1773-81.
39. Barrasa JI, Olmo N, Lizarbe MA, et al. Bile acids in the colon, from healthy to cytotoxic molecules. Toxicol In Vitro 2013;27:964-77.
40. Zaibi MS, Stocker CJ, O'Dowd J, et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 2010;584:2381-6.
41. Hamer HM, Jonkers DM, Bast A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009;28:88-93.
42. Zheng L, Kelly C, Campbell E, et al. Microbe-Host Crosstalk between Short-Chain Fatty Acids and Intestinal Epithelial HIF Provides a New Mechanism to Augment Tissue Barrier Function. FASEB J 2015;29: Supplement 282.6.
43. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014;63:1275-83.
44. Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009;26:1001-43.
45. Clifford MN. Diet-derived phenols in plasma and tissues and their implications for health. Planta Med 2004;70:1103-14.
46. Cardona F, Andrés-Lacueva C, Tulipani S, et al. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem 2013;24:1415-22.
47. Etxeberria U, Fernández-Quintela A, Milagro FI, et al. Impact of polyphenols and polyphenol-rich dietary sources on gut microbiota composition. J Agric Food Chem 2013;61:9517-33.
48. Carmody RN, Turnbaugh PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 2014;124:4173-81.
49. Nauts HC, McLaren JR. Coley Toxins-The First Century. Consensus on Hyperthermia for the 1990s. Adv Exp Med Biol 1990;267:483-500.
50. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971-6.
51. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967-70.
52. Anderson JC, Clarke EJ, Arkin AP, et al. Environmentally controlled invasion of cancer cells by engineered bacteria. J Mol Biol 2006;355:619-27.
53. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010;10:785-94.
54. Danino T, Prindle A, Kwong GA, et al. Programmable probiotics for detection of cancer in urine. Sci Transl Med 2015;7:289ra84.
55. Possemiers S, Bolca S, Verstraete W, et al. The intestinal microbiome: a separate organ inside the body with the metabolic potential to influence the bioactivity of botanicals. Fitoterapia 2011;82:53-66.
56. Baquero F, Nombela C. The microbiome as a human organ. Clin Microbiol Infect 2012;18:2-4.
57. Khoruts A, Sadowsky MJ, Hamilton MJ. Development of fecal microbiota transplantation suitable for mainstream medicine. Clin Gastroenterol Hepatol 2015;13:246-50.
58. Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013;145:946-53.